Sanofi: UBS maintains buy rating, trimming TP
(CercleFinance.com) - UBS maintains its "buy" rating on Sanofi shares, although has reduced its target price for them to 120 euros (from 121 euros), even though its new target still leaves upside potential 19% for the French pharmaceutical giant's stock.
"After a strong 1Q, margin improvements will be harder to come by in 2H but lack of binary catalysts and upside risk on what is there means we are still buyers," the broker said.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"After a strong 1Q, margin improvements will be harder to come by in 2H but lack of binary catalysts and upside risk on what is there means we are still buyers," the broker said.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.